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INTRODUCTION
Topical anti-inflammatory drugs usually associated to antibiotics 
continues to be the standard practice to reduce the inflammation 
resulting from intraocular surgery in spite disadvantages related to 
poor corneal penetration, difficulties with patient’s compliance and 
ocular toxicity(1-3).
Ozurdex® 0.7 mg (dexamethasone 0.7 mg implant) is a 0.46 mm 
in diameter and 6 mm in length FDA approved biodegradable im-
plant to be injected into the eye (vitreous) to treat different retinal 
and uveal pathologies. Several studies have shown that it’s a safety 
and efficient dispositive(4). It has also been used off label to treat non 
necrotizing non infectious scleritis(5). 
METHODS
Report review of 7 eyes of 7 patients who received a fragment 
of dexamethasone 0.7 mg implant after phacoemulsification and 
hydrophilic foldable IOL (Type 7B, Alcon®) implantation at the São 
Paulo Hospital, Federal University of São Paulo, comparing them to 
the fellow eyes. All the patients underwent bilateral cataract surgery, 
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ABSTRACT 
Purpose: To relate the outcomes of 7 eyes of 7 patients in which a dexamethasone 
0.7 mg implant (Ozurdex®) was placed inside the capsule bag after phacoemul-
sification and intraocular lens (IOL) implantation and compare with the fellow 
eyes, that were operated by the same technique and received dexamethasone 
eyedrops in the post-operatory. 
Methods: Report review of 7 eyes of 7 patients who received dexamethasone 
0.7 mg implant after phacoemulsification and IOL, comparing them to the fellow 
eyes. All the patients underwent bilateral cataract surgery, with one month interval, 
by the same technique and by experienced surgeons, without complications. Post 
operatory medication consisted of moxifloxacin eye drops for all the 14 eyes and 
topic dexamethasone for the 7 eyes that did not received the implant. 
Results: Nuclear cataract classification (according to LOCS III) was 3.28 ± 0.69 in 
the implant eye group and 3.14 ± 0.83 in the fellow eye group. Postoperative best 
spectacle correct visual acuity (BSCVA) was 0.85 ± 0.12 and 0.87 ± 0.13, respectively 
in the implant and fellow eye groups. The intraocular pressure remained stable 
and similar to the pre-operative measurements. Anterior chamber reaction and 
cornea edema were similar in both groups in the follow-up. Two of the four no 
sutured pellet migrated to the anterior chamber during the first post-operative 
week and had to be repositioned. Another no sutured pellet dislocated and 
remained partially inside the capsule bag. The 3 patients with IOL haptic-sutured 
pellet had no complications. 
Conclusions: In the present study, dexamethasone 0.7mg implant were effective 
in controlling the inflammation after phacoemulsification and IOL implantation, 
with no significant side effects. 
Keywords: Cataract/classification; Dexamethasone/administration & dosage; Ad -
ministration, topical; Phacoemulsification
RESUMO 
Objetivos: Relatar os resultados de 7 olhos de 7 pacientes em que foi realizado o 
implante de dexametasona 0,7 mg (Ozurdex®) no saco capsular após facoemulsifi-
cação e implante de lente intraocular (LIO) e comparar com os olhos contralaterais, 
que foram operados pela mesma técnica e receberam colírio de dexametasona no 
pós-operatório. 
Métodos: Relato de casos de 7 olhos de 7 pacientes que receberam o implante de 
dexametasona 0,7  mg após facoemulsificação e implante de LIO, comparando-os 
com os olhos contralaterais. Todos os pacientes foram submetidos a cirurgia de 
catarata bilateral, com intervalo de um mês entre as cirurgias, pela mesma técnica, 
por cirurgiões experientes e sem complicações. No pós-operatório foi utilizado colírio 
de moxifloxacino em todos os 14 olhos e dexametasona tópica nos olhos que não 
re ceberam o implante. 
Resultados: A classificação da catarata de acordo com o LOCS III foi de 3,28 ± 0,69 no 
grupo que recebeu o implante e 3,14 ± 0,83 no grupo de olhos contralateral. A acuidade 
visual com melhor correção foi de 0,85 ± 0,12 e 0,87 ± 0,13 respectivamente nos grupos 
com e sem implante. A pressão intraocular permaneceu estável e similar aos valores 
pré-operatórios. A reação de câmara anterior e o edema de córnea foram similares 
nos dois grupos. Dois dos 4 implantes sem sutura migraram para a câmara anterior 
durante a primeira semana de pós-operatório e necessitaram de reposicionamento. 
Outro implante sem sutura teve deslocamento e permaneceu parcialmente dentro 
do saco capsular. Os 3 pacientes com implante suturado não tiveram complicações. 
Conclusão: No presente estudo, o implante de dexametasona 0,7 mg foi efetivo no 
controle da inflamação intraocular após cirurgia de facoemulsificação e implante de 
LIO, sem efeitos colaterais significativos. 
Descritores: Catarata/classificação; Dexametasona/administração & dosagem; Ad -
ministração tópica; Facoemulsificação
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with one month interval, by the same technique and by experienced 
surgeons, without complications. Cataracts were graded according 
to the “Lens Opacities Classification System” III (LOCS III)(6). Patients 
were aged 58 to 71 years old. None of them had glaucoma or others 
ophthalmologic diseases.
Four eyes received a half pellet of the implant (3 mm) inside the 
bag, positioned between one of the IOL’s haptic and the equator of 
the capsular bag, without suturing. Three eyes received one-third 
pellet of the implant (2 mm), sutured to one of the IOL haptic with 
nylon 10.0. Postoperatory medication consisted of moxifloxacin 
eye drops, four times a day, during one week for all the 14 eyes 
and topic dexamethasone for the 7 eyes that did not received the 
implant. Patients were followed with biomicroscopy, tonometry and 
ophthalmoscopy on days 1, 3, 7, 30, 60 and 90 after surgery. Wide 
scanning angle Ultrasound Bio Microscopy (UBM) (50-MHz transdu-
cer, immersion technique, Vumax II, Sonomed) was used to evaluate 
the operated eyes on day 2. Anterior chamber reaction was graded 
according to SUN Working Group(7). None of them had glaucoma or 
others ophthalmologic diseases. 
The study was approved by the Institutional Review Board and 
followed the tenets of the Declaration of Helsinki. None of the pa-
tients had any expenses with the treatment and none of the authors 
received any type of compensation, including financial for the study.
RESULTS
Nuclear cataract classification (according to LOCS III) was 3.28 
± 0.69 in the implant eye group and 3.14 ± 0.83 in the fellow eye 
group, varying from 2 to 4 in both groups. In the first day, the cornea 
edema was 1.0 ± 0.53 in average in both groups and no detectable 
corneal edema in none of groups from the seventh day on. Preo-
perative best spectacle correct visual acuity (BSCVA) using Snellen 
chart was 0.25 ± 0.11 in the implant group and 0.27 ± 0.13 in the 
fellow eye group. On the third month postoperative, BSCVA was 
0.85 ± 0.12 and 0.87 ± 0.13, respectively. The intraocular pressure 
(IOP) remained stable and similar to the preoperative measurements 
during the postoperative visits. Anterior chamber reaction (ACR) is 
shown in figure 1.
The UBM performed on day 2 showed the positioning of the im -
plant and its relations with the iris, IOL haptic and the capsular bag 
(Figure 2). 
Two of the four no sutured pellet migrated to the anterior cham-
ber during the first post-operative week and had to be repositioned 
(Figure 3). Another no sutured pellet dislocated and remained par-
tially inside the capsule bag (Figure 4). The 3 patients with IOL hap-
tic-sutured pellet had no complications.
DISCUSSION
Reducing or eliminating the responsibility of administering pos-
toperative anti-inflammatory drops would be a significant benefit to 
patients since lack of drug compliance is frequent. 
The ideal postoperative drug delivery system for cataract sur-
gery should have high and prolonged drug level only at the desired 
site, with safety and short-acting enough to diminish the risks from 
side effects or allergy(8). Topical anti-inflammatory medication after 
cataract surgery continues to be the standard practice, but it does 
not have some of this related attributes. The intraocular absorption 
of the topical preparation is low, with fluctuations in the anterior 
chamber concentration and may be absorbed systemically by the 
nasal and gastric mucosa(9). Options like subconjunctival injection, 
collagen shield and intracameral injection fail to provide a therapeu-
tic drug level of more than several hours(1). Drugs like Surodex (Oculex 
Pharmaceuticals, Inc., Sunnyvale, CA) containing dexamethasone 60 
micrograms was used after phacoemulsification and its safety and 
efficacy has been related in the literature(8,10). 
Figure 1. Average clinical assessment of anterior chamber reaction in the group with 
dexamethasone implant and in the fellow eye (control).  Anterior chamber reaction was 
graded according to SUN Working Group(7). 
Figure 2. Dexamethasone 0.7 mg implant and its relations with the iris, IOL haptic and 
the capsular bag.
Figure 3. Dexamethasone 0.7 mg implant migration to the anterior chamber before 
and after repositioning.
Figure 4. Non-sutured pellet on days 7 (left) and 90 (right) postoperative.
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In our study we have reported the outcomes of 7 patients who 
received a dexamethasone 0.7 mg implant inside the bag after pha-
coemulsification and IOL implantation. 
Clinical slit-lamp assessment of anterior chamber flare and cells 
showed normal follow-up for the postoperative comparing with eye 
drops corticosteroids in the fellow eye. Chang et al.(11) report that 
rescue medication was required for intraocular inflammation in 12% 
of patients with a Surodex® implant by the end of a 2-month study. 
We found no rebound inflammation in the seven patients and there 
were no need of corticosteroids eye drops complementation in any 
of them.
The IOP remained stable during all the follow-up visits and were 
similar to the fellow eye. There were no needs of antihypertensive 
medications in any of the patients. 
No significant edema was detected in any of the follow-up visits. 
BSCVA was better than preoperative in all the seven patients and 
were similar to the fellow eye. 
An ultrasound biomicroscopy (UBM) was performed on day 2 
to evaluate the positioning of the implant in the non-dilated eye 
(Figu re 3). Since there are reports of Surodex migration and remnants 
in the anterior chamber in the literature(8,10). In our study, the dexame-
thasone 0.7 mg implant was placed sutureless in the first four patients 
and there was a migration to the anterior chamber in two of them 
and a migration from the original intraoperative position in another 
one, almost reaching the visual axis (Figure 4). Because of this, the 
other 3 implants were sutured on the IOL haptic and remained stable 
throughout the follow-up.
Larger series would be necessary to compare the potential bene-
fits of reduced systemic side effects and toxicity of dexamethasone 
implant after phacoemulsification. 
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